Masayuki Nakamori

List of Publications by Year
in descending order

61	3,456	159585 30	144013 57
papers	citations	h-index	g-index

65	65	65	3247
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	CAG repeat-binding small molecule improves motor coordination impairment in a mouse model of Dentatorubralâ€“pallidoluysian atrophy. Neurobiology of Disease, 2022, 163, 105604.	4.4	11
2	Cellular Senescence and Aging in Myotonic Dystrophy. International Journal of Molecular Sciences, 2022, 23, 2339.	4.1	5
3	Expanded CUG Repeat RNA Induces Premature Senescence in Myotonic Dystrophy Model Cells. Frontiers in Genetics, 2022, 13, 865811.	2.3	4
4	Cell type-specific abnormalities of central nervous system in myotonic dystrophy type 1. Brain Communications, 2022, 4, .	3.3	6
5	Pharmacotherapy alleviates pathological changes in human direct reprogrammed neuronal cell model of myotonic dystrophy type 1. PLoS ONE, 2022, 17, e0269683.	2.5	0
6	Targeting Expanded Repeats by Small Molecules in Repeat Expansion Disorders. Movement Disorders, 2021, 36, 298-305.	3.9	7
7	Alphaâ€synuclein dynamics in induced pluripotent stem cellâ€derived dopaminergic neurons from a Parkinsonâ€™s disease patient (PARK4) with SNCA triplication. FEBS Open Bio, 2021, 11, 354-366.	2.3	7
8	FAN1 exo- not endo-nuclease pausing on disease-associated slipped-DNA repeats: A mechanism of repeat instability. Cell Reports, 2021, 37, 110078.	6.4	19
9	The Dimeric Form of 1,3â€Diaminoisoquinoline Derivative Rescued the Misâ€splicing of Atp2a1 and Clcn1 Genes in Myotonic Dystrophy Typeâ€…1 Mouse Model. Chemistry - A European Journal, 2020, 26, 14305-14309.	3.3	10
10	A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo. Nature Genetics, 2020, 52, 146-159.	21.4	110
11	Alternative splicing of clathrin heavy chain contributes to the switch from coated pits to plaques. Journal of Cell Biology, 2020, 219, .	5.2	31
12	Combination Treatment of Erythromycin and Furamidine Provides Additive and Synergistic Rescue of Mis-splicing in Myotonic Dystrophy Type 1 Models. ACS Pharmacology and Translational Science, 2019, 2, 247-263.	4.9	20
13	A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20991-21000.	7.1	20
14	The myotonic dystrophy health index: Japanese adaption and validity testing. Muscle and Nerve, 2019, 59, 577-582.	2.2	5
15	Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting Î±-synuclein as a novel therapy for Parkinsonâ€™s disease. Scientific Reports, 2019, 9, 7567.	3.3	65
16	Modulating RNA secondary and tertiary structures by mismatch binding ligands. Methods, 2019, 167, 78-91.	3.8	10
17	Human Genomic Safe Harbors and the Suicide Gene-Based Safeguard System for iPSC-Based Cell Therapy. Stem Cells Translational Medicine, 2019, 8, 627-638.	3.3	26
18	Nucleic Acidâ€“Based Therapeutics for Parkinson's Disease. Neurotherapeutics, 2019, 16, 287-298.	4.4	45

#	Article	IF	Citations
19	Straightjacket/Î±2Î´3 deregulation is associated with cardiac conduction defects in myotonic dystrophy type 1. ELife, 2019, 8, .	6.0	8
20	Macroscopic and microscopic diversity of missplicing in the central nervous system of patients with myotonic dystrophy type 1. NeuroReport, 2018, 29, 235-240.	1.2	8
21	Therapeutic Development in Myotonic Dystrophy. , 2018, , 203-214.		0
22	A Dimeric 2,9â€Ÿdiaminoâ€•1,10â€•phenanthroline Derivative Improves Alternative Splicing in Myotonic Dystrophy Typeâ€…1 Cell and Mouse Models. Chemistry - A European Journal, 2018, 24, 18115-18122.	3.3	27
23	Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple Mechanisms. ACS Chemical Biology, 2018, 13, 2708-2718.	3.4	26
24	Myotonic dystrophy type 1 patient-derived iPSCs for the investigation of CTG repeat instability. Scientific Reports, 2017, 7, 42522.	3.3	34
25	Aberrant Myokine Signaling in Congenital Myotonic Dystrophy. Cell Reports, 2017, 21, 1240-1252.	6.4	40
26	Disrupted prenatal RNA processing and myogenesis in congenital myotonic dystrophy. Genes and Development, 2017, 31, 1122-1133.	5.9	80
27	Renal dysfunction can be a common complication in patients with myotonic dystrophy 1. Journal of the Neurological Sciences, 2016, 368, 266-271.	0.6	6
28	Oral administration of erythromycin decreases <scp>RNA</scp> toxicity in myotonic dystrophy. Annals of Clinical and Translational Neurology, 2016, 3, 42-54.	3.7	55
29	Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy. Nature Communications, 2016, 7, 11067.	12.8	155
30	Myotonic Dystrophy. , 2016, , 39-61.		4
31	Actinomycin D Specifically Reduces Expanded CUG Repeat RNA in Myotonic Dystrophy Models. Cell Reports, 2015, 13, 2386-2394.	6.4	74
32	Large expansion of CTGâ€¢CAG repeats is exacerbated by MutSÎ² in human cells. Scientific Reports, 2015, 5, 11020.	3.3	37
33	Biological Efficacy and Toxicity of Diamidines in Myotonic Dystrophy Type 1 Models. Journal of Medicinal Chemistry, 2015, 58, 5770-5780.	6.4	31
34	A Kir3.4 mutation causes Andersenâ€“Tawil syndrome by an inhibitory effect on Kir2.1. Neurology, 2014, 82, 1058-1064.	1.1	59
35	Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects. Nucleic Acids Research, 2014, 42, 6591-6602.	14.5	46
36	Reducing Levels of Toxic RNA with Small Molecules. ACS Chemical Biology, 2013, 8, 2528-2537.	3.4	71

#	Article	IF	Citations
37	Splicing biomarkers of disease severity in myotonic dystrophy. Annals of Neurology, 2013, 74, 862-872.	5.3	215
38	Detection of Slipped-DNAs at the Trinucleotide Repeats of the Myotonic Dystrophy Type I Disease Locus in Patient Tissues. PLoS Genetics, 2013, 9, e1003866.	3.5	62
39	Rational Design of Bioactive, Modularly Assembled Aminoglycosides Targeting the RNA that Causes Myotonic Dystrophy Type 1. ACS Chemical Biology, 2012, 7, 1984-1993.	3.4	57
40	From dynamic combinatorial â€˜hitâ€™ to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy. Nucleic Acids Research, 2012, 40, 6380-6390.	14.5	69
41	Design of a Bioactive Small Molecule That Targets the Myotonic Dystrophy Type 1 RNA via an RNA Motifâ€“Ligand Database and Chemical Similarity Searching. Journal of the American Chemical Society, 2012, 134, 4731-4742.	13.7	129
42	Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature, 2012, 488, 111-115.	27.8	435
43	Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of CaV1.1 calcium channel. Human Molecular Genetics, 2012, 21, 1312-1324.	2.9	146
44	Muscleblind-Like 1 Knockout Mice Reveal Novel Splicing Defects in the Myotonic Dystrophy Brain. PLoS ONE, 2012, 7, e33218.	2.5	79
45	Identification of restriction endonucleases sensitive to 5-cytosine methylation at non-CpG sites, including expanded (CAG)n/(CTG)n repeats. Epigenetics, 2011, 6, 416-420.	2.7	13
46	A hidden ancestral legacy trumped. Nature, 2011, 478, 46-47.	27.8	0
47	Stabilization of Expanded (CTG)â€¢(CAG) Repeats by Antisense Oligonucleotides. Molecular Therapy, 2011, 19, 2222-2227.	8.2	65
48	Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues. Human Molecular Genetics, 2011, 20, 1-15.	2.9	129
49	Replacement of the myotonic dystrophy type 1 CTG repeat with 'non-CTG repeat' insertions in specific tissues. Journal of Medical Genetics, 2011, 48, 438-443.	3.2	7
50	The Role of Alpha-Dystrobrevin in Striated Muscle. International Journal of Molecular Sciences, 2011, 12, 1660-1671.	4.1	27
51	Bidirectional transcription stimulates expansion and contraction of expanded (CTG)â€¢(CAG) repeats. Human Molecular Genetics, 2011, 20, 580-588.	2.9	99
52	Epigenetic changes and non-coding expanded repeats. Neurobiology of Disease, 2010, 39, 21-27.	4.4	32
53	Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18551-18556.	7.1	234
54	Scaled-down genetic analysis of myotonic dystrophy type 1 and type 2. Neuromuscular Disorders, 2009, 19, 759-762.	0.6	21

#	Article	IF	Citations
55	Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1. Human Molecular Genetics, 2007, 16, 2834-2843.	2.9	92
56	Altered mRNA splicing of dystrophin in type 1 myotonic dystrophy. Muscle and Nerve, 2007, 36, 251-257.	2.2	42
57	Endoplasmic reticulum stress in myotonic dystrophy type 1 muscle. Acta Neuropathologica, 2007, 114, 527-535.	7.7	52
58	Sacsin-related ataxia caused by the novel nonsense mutation Arg4325X. Journal of Neurology, 2006, 253, 1372-1373.	3.6	12
59	Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in myotonic dystrophy type 1. Human Molecular Genetics, 2005, 14, 2189-2200.	2.9	247
60	Improvement of Anti-Hu-associated Paraneoplastic Sensory Neuropathy after Chemoradiotherapy in a Small Cell Lung Cancer Patient.. Internal Medicine, 2001, 40, 1140-1143.	0.7	21
61	Therapeutic approach for myotonic dystrophy: Recent advances in translational research. Neurology and Clinical Neuroscience, 0, , .	0.4	0